• Stacy Norman
• 22 Apr, 2021

Clinical trials will start on Thursday with the help of 510 healthy volunteers between the ages of 18 and 55. The vaccination uses a weakened version of a common cold virus with genes coding for the coronavirus's damaging weapon, its “spikes”. The vaccine uses the “spikes” against its self by raising antibodies that cling to them allowing the immune system to latch on and destroy the virus.
Read more...